Jan 28 (Reuters) - Drugmaker Incyte INCY.O said on Tuesday
its cream to treat a type of skin disease met its main goal of
improving skin clarity in patients with atopic dermatitis in a
late-stage study.
Atopic dermatitis is a common chronic disease characterized
by inflammation of the skin.
The study was testing the ruxolitinib cream in adolescent
and adult patients aged 12 years and above.